TB-500 is a synthetic injectable fragment of Thymosin Beta-4, used off-label to promote systemic tissue repair, reduce inflammation, and accelerate healing across multiple injury sites simultaneously.
What it does
TB-500 works primarily by binding G-actin — the globular, unpolymerized form of the protein that forms the cell's structural scaffolding. By sequestering G-actin, TB-500 regulates how cells physically move, which is the fundamental requirement for tissue repair. Fibroblasts (the cells that lay down new connective tissue), endothelial cells (which line blood vessels), and immune cells all depend on actin dynamics to migrate toward a wound. TB-500 modulates that migration at a systemic level, meaning it circulates through the body rather than acting only at one local site Joseph 2025 Yanhai 2025.
The G-actin binding also feeds into a second pathway. When TB-500 sequesters actin, it frees up a transcription regulator called MRTF-A (myocardin-related transcription factor A), which then activates SRF (serum response factor) target genes. Those genes control production of collagen, fibronectin, smooth muscle actin, and VEGF — the vascular endothelial growth factor that triggers angiogenesis (new blood vessel formation). Upregulating VEGF systemically is part of why TB-500 appears to support healing across multiple tissues at once, not just at a single injury site Wandi 2024 Youjun 2025.
Beyond cell migration and vessel growth, TB-500 inhibits NF-κB — a master transcription factor that drives inflammatory signaling — thereby reducing circulating cytokines like TNF-α, IL-6, and IL-1β Yuxin 2024. It also upregulates matrix metalloproteinases (MMPs), enzymes that break down damaged extracellular matrix (the structural scaffold between cells), clearing the way for organized collagen deposition. In cardiac tissue specifically, it has been shown to support cardiomyocyte survival after ischemia and to activate cardiac progenitor cells NCT05485818. One additional effect documented in research is follicular vascularization — VEGF-driven blood supply improvements around hair follicles that appear to extend the anagen (active growth) phase Alexandra 2025.
What the evidence shows
Wound and tissue healing Moderate-to-strong in vitro and animal data; early-phase human trial data from pressure ulcer and venous stasis ulcer studies
Two completed clinical trials tested full-length Thymosin Beta-4 (of which TB-500 is a fragment) in patients with pressure ulcers and venous stasis ulcers NCT00382174 NCT00832091. Both were small, early-phase studies focused on safety and preliminary efficacy, and neither generated published large-scale results — but the trials established tolerability in humans. In vitro and animal work is more extensive: TB-500 has been shown to promote corneal wound repair Joseph 2025 Gabriel 2023, fat graft survival by modulating adipose-derived stem cells Wandi 2024, and bacterial keratitis resolution Yuxin 2024. A 2023 combination study found Tβ4 paired with VIP protected corneal epithelial cells against hyperglycemia-induced damage Shukkur 2023. The mechanistic picture is consistent; the human trial evidence is thin.
Cardiac protection and recovery Animal evidence is solid; one ongoing human trial in acute myocardial infarction
Preclinical data show Thymosin Beta-4 reduces myocardial infarct size, limits fibrosis, and activates cardiac progenitor cells after ischemic injury. A registered human trial is currently evaluating safety and efficacy of Thymosin Beta-4 in acute myocardial infarction patients NCT05485818. Results are not yet published. Until that data is available, cardiac applications in humans remain speculative — though the mechanism is well-characterized and biologically plausible.
Anti-inflammatory and immune modulation Mechanistic evidence in vitro and animal models; limited direct human data
TB-500's suppression of NF-κB and downstream cytokines (TNF-α, IL-6, IL-1β) is documented in corneal infection models Yuxin 2024 and shrimp immunity research that maps conserved mechanisms Changhong 2023. The proteomic profile of mesenchymal stromal cell secretomes includes Tβ4 as a notable anti-inflammatory mediator Alexandra 2025. No human randomized trials have specifically targeted TB-500's anti-inflammatory effects as a primary endpoint.
Bone and neural tissue repair Early preclinical and in vitro evidence only
A 2025 study demonstrated that Thymosin Beta-4-modified hyaluronic acid hydrogel with exosomes promoted stem cell homing and coupled neural, vascular, and bone repair in cranial defect models Yanhai 2025. Separately, engineered extracellular vesicles incorporating Tβ4 rescued cellular senescence in diabetic wound contexts Youjun 2025. These are promising mechanistic findings, but they are not yet translated to human studies.
Doping detection / biomarker research Rat model pharmacokinetic data; relevant for understanding metabolism
A 2023 study identified a urinary metabolite (Ac-Tβ1-14) as a detectable biomarker of Thymosin Beta-4 administration in rats, with implications for anti-doping testing Asiqur 2023. TB-500 is prohibited in competition by WADA as a peptide hormone mimetic. This metabolite work suggests detection windows exist, though human pharmacokinetic data remain sparse.
How it's used
In studies and self-reported protocols, doses range from 2 mg once weekly (maintenance or mild injury) up to 2–2.5 mg twice weekly for a 4–6 week loading phase, followed by weekly dosing. High-end protocols for severe injuries report up to 5 mg twice weekly, though no clinical trials have validated this dose. TB-500 is administered subcutaneously (injected under the skin) or intramuscularly. Plasma half-life is approximately 2–3 hours, but tissue distribution is thought to persist considerably longer. Timing within the day does not appear to affect outcomes based on available data. TB-500 is the synthetic fragment form; it is not identical to full-length Thymosin Beta-4 used in registered trials.
Side effects and safety
Reported side effects in self-reported use are generally mild: injection site irritation, transient head rush shortly after injection, and mild lethargy. Moderate effects reported include headache and temporary fatigue. No severe adverse events have been documented in the literature specific to TB-500 as a fragment, though the human safety database is small. Because TB-500 upregulates VEGF and promotes angiogenesis, it carries a theoretical risk of accelerating growth in pre-existing tumors — the same concern applies to any pro-angiogenic agent. It is considered an absolute contraindication in active cancer and pregnancy, and a relative contraindication in anyone with a history of malignancy or currently receiving anti-angiogenic therapy. Long-term safety data in humans essentially does not exist. The metabolic fate of the synthetic fragment differs from full-length Tβ4, and no long-term human studies have characterized chronic exposure effects Asiqur 2023.
Bottom line
TB-500 has a coherent and well-studied mechanism, solid preclinical evidence across wound healing, inflammation, and cardiac contexts, and preliminary human tolerability data from early-phase ulcer trials — but no large, published randomized controlled trials in humans. It is a reasonable subject of interest for someone researching systemic tissue repair, but anyone using it is operating well ahead of the clinical evidence base.